Stockreport

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA ® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle [Read more]